For Employers

PROMISE TO MAP | Omada's approach to build safety and security into AI-powered products

PROMISE TO MAP is Omada's approach to build safety and security into AI-powered products.

Read Resource

Omada Health Reports Second Quarter 2025 Results

Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.

Read Article

30 days ago

Meet Heather

Meet Heather, a real Omada member from Atlanta, GA in the Omada for Prevention & Weight Health program with the embedded GLP-1 enhanced care track. Here's her journey.

Watch Video

Error - something went wrong!

Become an Omada Insider, subscribe to our monthly newsletter

Thank you!

30 days ago

Meet Niki

Niki got personalized support and accountability from her coach to make small changes to build lasting healthy habits. Here's her journey.

Watch Video

30 days ago

Meet Stephanie

She has multiple chronic conditions and was able to get support from her entire care team to make healthy changes. Here's her journey.

Watch Video

30 days ago

Meet Christina

Christina not only got support to make small changes to build healthy habits but with the support Christina got between visits, she was able to lower her medication dosage. Here’s her journey.

Watch Video

about 1 month ago

Patients, providers and payers alike are investing in GLP-1 medications - but are they seeing the value they expected?

In this ~2-minute video, Omada's Senior Director of Clinical and Translational Research, Sarah Linke, summarizes findings of our July 2025 clinical white paper on GLP-1 Persistence

Read Article

about 1 month ago

Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.

Read Article

2 months ago

Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises

Read Article

2 months ago

GLP-1 Medication Persistence, a Key Component of Weight Loss

Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.

Read Resource

3 months ago

Omada Health Announces Pricing of Initial Public Offering

Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe

Read Article

3 months ago

Omada Health Announces Launch of Initial Public Offering

Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”

Read Article

Become an Omada Insider, subscribe to our monthly newsletter

Sign Me Up

3 months ago

Omada Horizon Day - The Food Experience 2025

On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!

Watch Video

4 months ago

3 Reasons Behavior Change Support is Vital to Obesity Care

Why GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.

Read Article

4 months ago

5 Key Lessons Learned in the U.S. about Weight Loss Drugs

This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.

Read Article

4 months ago

Building Self Efficacy in the Era of GLP-1s

Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.

Read Article

4 months ago

Lower Acute Healthcare Utilization Associated with Virtual Cardiometabolic Health Programs

This analysis found that lifestyle-focused virtual health program to support cardiometabolic disease management may lead to meaningful reductions in high-cost acute care encounters.

Read Article

4 months ago

Life After GLP-1s: A Real-World Population Snapshot

This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.

Read Article

4 months ago

New Indications, Promising Outcomes, and Third-Party Prescribing

As the GLP-1 conversation evolves, Omada Health is updating its industry FAQs to deliver timely data and insights for virtual care buyers.

Read Article

5 months ago

Why Honesty is the Best Policy as AI Continues Shaping Healthcare: Q&A with Lucia Savage, Chief Privacy & Regulatory Officer

Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.

Read Article

The Omada Platform

PROGRAMS

Insights Lab

WHO WE SERVE

About Omada

Omada For Employers

For Employers

PROMISE TO MAP | Omada's approach to build safety and security into AI-powered products

Omada Health Reports Second Quarter 2025 Results

Meet Heather

Meet Niki

Meet Stephanie

Meet Christina

Patients, providers and payers alike are investing in GLP-1 medications - but are they seeing the value they expected?

Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

GLP-1 Medication Persistence, a Key Component of Weight Loss

Omada Health Announces Pricing of Initial Public Offering

Omada Health Announces Launch of Initial Public Offering

Omada Horizon Day - The Food Experience 2025

3 Reasons Behavior Change Support is Vital to Obesity Care

5 Key Lessons Learned in the U.S. about Weight Loss Drugs

Building Self Efficacy in the Era of GLP-1s

Lower Acute Healthcare Utilization Associated with Virtual Cardiometabolic Health Programs

Life After GLP-1s: A Real-World Population Snapshot

New Indications, Promising Outcomes, and Third-Party Prescribing

Why Honesty is the Best Policy as AI Continues Shaping Healthcare: Q&A with Lucia Savage, Chief Privacy & Regulatory Officer

Become an Omada Insider